Javascript is disabled

Daniel A. Arber, MD is the Donald West and Mary Elizabeth King Professor and Chair of Pathology at the University of Chicago. He specializes in the diagnosis of leukemia, lymphoma and splenic tumors. Dr. Arber’s primary research interests include the development of prognostically significant classification systems of hematopoietic tumors as well as the study of acquired genetic changes in leukemia and lymphoma. Dr. Arber has authored or co-authored more than 300 peer-reviewed journal articles, book chapters, and reviews and has written/edited ten medical text books. He is on the editorial board of seven major pathology journals. He is the pathologist for the Eastern Cooperative Oncology Group Leukemia Committee and was a senior advisor for the 2016 World Health Organization (WHO) Classification of hematopoietic tumors and a co-author of the National Comprehensive Cancer Network (NCCN) guidelines for the treatment of acute myeloid leukemia. He was co-chair of the American Society of Hematology/College of American Pathologist Expert Panel on Acute Leukemia Workup Guidelines, was a member of the College of American Pathologists – Center for Disease Control and Prevention Guideline Metrics Expert Panel, is a past president of the Society for Hematopathology and a past member of the Board of Directors for the US & Canadian Academy of Pathology.

Adam Bagg is a Professor of Pathology and Laboratory Medicine at the University of Pennsylvania in Philadelphia who divides his time between directing Hematology, attending in hematopathology, teaching and research. He was previously Medical Director of the Cancer Cytogenetics Laboratory. He has received numerous research grants, including some from the NIH, and teaching awards. For the past 12 years (2010-2021), he was voted by his peers as one of Philadelphia’s “Top Doctors”, the only hematopathologist in the Philadelphia region (which includes five academic medical centers, as well as other large community practices) to be so recognized. Dr. Bagg has lectured extensively nationally (including at USCAP, ASCP, AMP, CAP, ACLPS, AACC, and ASH, as well as giving grand rounds at a number of prestigious universities) and internationally (at EAHP, ISLH, EBMWG, IAP, in over 20 countries). He has over 200 full-length publications most in the realm of the molecular pathology of hematologic malignancies. A publication that he was a coauthor on (CART19 T-cells to treat CLL) was the most downloaded article in Science Translational Medicine for 2011. He is an Associate Editor of the Journal of Molecular Diagnostics and on the Editorial Board of Advances in Anatomic Pathology.

Former Professor of Immunology at Nancy university and University Hospital and currently Professor of Hematology at Nantes University and University Hospital, in France, I am there head of the Hematology Biology Department which performs integrated diagnosis in benign and malignant hematology. I also have several national and international activities. I have managed the leadership of Workpackage 10 at the European LeukemiaNet (ELN) and of a Scientific Working Group of the European Hematology Association (EHA). At EHA, I am also in the task force on IVD. I am a board member of the ISLH and a councillor of ICCS.

Dr. Czader is a Professor of Pathology and a Director of Hematopathology in the Department of Pathology and Laboratory Medicine at Indiana University in Indianapolis. She received her M.D. degree from Poznan University of Medical Sciences and Ph.D. from Karolinska Institute in Stockholm. Dr. Czader completed a residency in Anatomic and Clinical Pathology, and hematopathology fellowship at the John Hopkins Medical Institutions in Baltimore, Maryland. After joining Indiana University, Dr. Czader focused on developing diagnostic approaches for hematopoietic malignancies, integration of hematopathology testing, and laboratory efficiency and safety. She serves or has served on editorial boards of pathology journals and as a consultant for industry projects. Dr. Czader has been active in the Society for Hematopathology including serving as a member-at-large, Secretary/Treasurer and President of this organization. She has lectured and presented at meetings of the International Clinical Cytometry Society, Society for Hematopathology, European Association for Haematopathology, European Bone Marrow Working Group, United States and Canadian Academy of Pathology and American Society for Clinical Pathology. Dr. Czader has published in many prominent pathology and clinical journals, authored book chapters and is an editor of a book Methods in Molecular Biology Hematological Malignancies.

Dr Mats Ehinger is Associate Professor of Hematopathology at Lund University and a Hematopathologist and Cytopathologist at Lund University Hospital, where he is Director of the Hematopathology Department. Dr Ehinger received his MD from Lund University and trained in Anatomic Pathology and Hematopathology at Lund University Hospital and Karolinska University Hospital. He is currently Chairman of the Swedish Working Group of Hematopathology and an active member or the European Bone Marrow Working Group. He has arranged numerous courses in hematopathology at the national level. His research interests are mainly in the development of techniques for measurable residual disease detection in leukemia. Dr Ehinger is an author of almost 100 peer-reviewed publications, reviews and chapters. He is a Senior Reviewer and author of several chapters in the upcoming first edition of the WHO International Reporting System for Lymph Node, Spleen and Thymus Cytopathology. Dr Ehinger is strongly committed to education in hematopathology and has lectured on the diagnosis of leukemias and lymphomas at numerous courses. Outside work, he is a passionate and mediocre chess player with a current ELO-rating of 1635, steadily improving.

Falko Fend, MD, is Professor of Pathology and Chairman of the Institute of Pathology and Neuropathology and Reference Center for Hematopathology at the Eberhard-Karls University in Tübingen, Germany. He did his postgraduate training in the Departments of Pathology and Internal Medicine at Innsbruck University and joined the Department of Pathology as staff pathologist in 1991. From 1997-1999, he worked as research fellow at the Laboratory of Pathology, National Cancer Institute, NIH, Bethesda, with Mark Raffeld and Elaine Jaffe. In 1999, he was appointed Associate Professor of Pathology at the Institute of Pathology of the Technical University Munich. In 2007, he moved to his current position at the University of Tübingen. His main research interest focuses on the pathology and molecular genetics of malignant lymphomas and innovative molecular pathology. He obtained competitive funding from multiple national and international grant agencies, has authored or co-authored over 400 publications and has contributed to major textbooks and reference works. He serves/-ed as member of the executive boards of the German Society of Pathology, the European Association of Haematopathology and as Chairman of the European Bone Marrow Working Group.

Umberto Gianelli is full professor of Anatomic Pathology at the University of Milan, past-chair of the European Bone Marrow Working Group and Chair of the Hematopathology Section of the Pathology Department of the Fondazione IRCCS Ca’ Granda – Ospedale Maggiore Policlinico of Milan, Italy. He is author of more than 130 indexed paper and his research field spans among myeloid and lymphoid neoplasms, with a particular focus on myeloproliferative neoplasms. He’s been invited speaker in several international meetings and is involved in several training activities for pathologists.

Prof Dr Torsten Haferlach is a hematologist and expert in the field of leukemia. In 2005 he set up the Munich Leukemia Laboratory (www.mll.com) together with three colleagues from complementary disciplines. Today the lab processes with a team of 210 employees over 100,000 blood or bone marrow samples per year, his practice treats more than 5,000 patients. His team contributes to standard and cutting-edge diagnostics in leukemia: over 620 articles have been published together with many international collaborators in top ranking, peer-reviewed journals since the lab’s inception. NGS including WGS and WTS and several workflows including new AI tools are established and accredited in MLL.

Dr Robert Hasserjian is Professor of Pathology at Harvard Medical School and a Hematopathologist at Massachusetts General Hospital, where he is Director of the Hematopathology Fellowship Program. Dr Hasserjian received his MD from Harvard and trained in Anatomic Pathology and Hematopathology at Brigham and Women's Hospital. He is currently President-Elect of the Society for Hematopathology and he was co-organizer of the 2017 Society for Hematopathology/European Association for Hematopathology Annual Workshop, with the topic of “Molecular Genetics of Hematopoietic Neoplasms”. His research interests are in the discovery of pathologic and genetic features associated with the biologic behavior of myeloid and lymphoid neoplasms, particularly myelodysplastic syndromes and acute myeloid leukemia. Dr Hasserjian is an author of over 200 peer-reviewed publications, reviews, and chapters and is the editor of the textbook “Diagnosis of Blood and Bone Marrow Disorders” (Springer, 2018). He was a Senior Reviewer and author of multiple chapters of the Revised 4th Edition WHO Classification of Myeloid Neoplasms published in 2017. Dr Hasserjian is strongly committed to education in hematopathology and has lectured on the diagnosis of leukemias, other bone marrow disorders, and lymphomas at numerous courses and international pathology meetings across the Americas, Europe, and Asia.

Konnie Hebeda is hematopathologist at the Radboudumc in Nijmegen (NL) and currently secretary of the Dutch Society for Hematopathology and secretary of the European Bone Marrow Working Group. She is head of the ESP Advanced training Centre for Hematopathology in Nijmegen. Her main interests are bone marrow pathology and lymphoproliferative disorders in the context of immunodeficiency and cancer predisposition. Konnie Hebeda became fascinated by pathology after her PhD in photodynamic therapy in brain tumours. After her pathology training she obtained a fellowship of the Dutch Cancer Society to further specialize in hematopathology during 2 years with Dr. E. Jaffe (NIH, Bethesda, USA), Dr. J. Holden (Emory University Hospital, Atlanta, USA), Dr. J. van Dongen (ErasmusMC, NL) and prof. R. Willemze (Leiden UMC, NL).

Dr. Hyjek is an Associate Member of Pathology at Moffitt Cancer Center, and Associate Professor in Department of Oncological Science at Morsani College of Medicine, University of South Florida, Tampa, FL, USA. She earned her MD and PhD degree from Medical University in Lodz, Poland. She completed a residency in Anatomic & Clinical Pathology and Fellowship in Hematopathology at New York Presbyterian Hospital-Weill College of Cornell Medical College, New York, NY, and post-doctoral fellowship in Molecular Biology/Immunology at Fels Institute for Cancer and Molecular Biology/Temple University School of Medicine, and Department of Microbiology and Immunology at Thomas Jefferson University in Philadelphia. She was most recently an Associate Professor in Department of Pathology, Hematopathology Section at the University of Chicago. Dr. Hyjek clinical interest is in myeloid neoplasms and lymphoproliferative disorders, with focus on myelodysplastic/myeloproliferative neoplasms. She has also interest in immunohistochemistry for diagnosis of hematopoietic neoplasms and lymphoid proliferations and new biomarkers development, and flow cytometry for diagnosis of acute leukemias and monitoring of minimal residual disease. Dr. Hyjek research interest is focused on studying the relationship between cancer cells and microenvironment, using morphology, flow cytometry, immunohistochemistry, and molecular techniques. She published more than 100 publications in peer reviewed journals.

Having received my M.D. certificate 1995 at the University of Göttingen I have been working as a Research Fellow at Internal Medicine/Hematology and Oncology, University of Göttingen from 1995 to 1998 and at Dept. of Internal Medicine III, University of Munich from 1998 to 2005. In 1999 I completed my M.D. thesis and received the Dr. med. Certificate at Universtity of Göttingen. From 2001 to 2005I have been heading the Flow Cytometry Department at Laboratory for Leukemia Diagnostics, University of Munich. I specialized in Internal Medicine as well as in Hematology and Medical Oncology in 2003. In 2004 I received my postdoctoral lecture qualification at University of Munich. Since August 2005 I am co-owner, Managing Director and Head of Flow Cytometry Department at MLL Munich Leukemia Laboratory. Since 2007 I am acting as reviewer for hematology for DAkkS (German accreditation body) and since 2013 I am member of the DAkkS Sectorial Committee on medical laboratories. In 2013 I have been appointed as Professor. Focus of my diagnostic and scientific activities has been the assessment of MRD in AML as well as diagnostics in MDS.

MD, PhD, senior consultant, Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital in Lund, Sweden. He received his degree and specialist education in internal medicine and Hematology at the Institute of Hematology, University Clinical Center in Belgrade, Yugoslavia in 1998. Moved to Sweden in 2003 and worked at the Department of Hematology and the Norrlands University Hospital in Umeå until 2008 since when he moved to live and work in Lund. He is Associate Professor of Clinical Hematology at the Medical Faculty, Lund University. As author he published more than 70 articles in journals as Blood, Blood Advances, British Journal of Haematology, Haematologica, Leukemia. Served as a peer-review for Blood, American Journal of Hematology, Cancers, European Journal of Hematology, Oncotarget and many other journals. His special research interest is myeloid neoplasms especially AML and Allogeneic stem cell transplantation. He is involved as investigator in international phase I-III clinical trials for treatment of MDS, MPN and AML and several research projects based on the Swedish AML Registry. At present he serves as a chairman of the swedish AML group and founding member of the Steering committee of the newly established nordic AML group.

Roos J. Leguit (1976) is a senior consultant in haematopathology and cytopathology and works at the University Medical Centre Utrecht (the Netherlands) since 2006. She graduated from medical school at the University Utrecht (bachelor and master with honors), and completed her residency in Pathology at the Academic Medical Center, Amsterdam. She has been the local Head of the Cytology department (2011-2013 and 2015-2017), and Program Director of the Pathology Training Program (2012-2017). To enhance her expertise in haematopathology, she visited the Universitätsklinikum in Frankfurt as well as Cornell University, NY, USA. She is chair of the regional lymphoma panel, and member of the Dutch Society for Haematopathology as well as the Dutch National Bone Marrow Working group. Internationally, she is a member of the European Bone Marrow Working Group (EBMWG) and the International morphology board of the European Working Group of MDS in Children (EWOG-MDS), both for over ten years. As an active member, she chaired several sessions at EBMWG and EAHP meetings and organized the XIII EBMWG International Course and Workshop on Bone Marrow Pathology in Utrecht in 2017. Her research focuses on CTGF/CCN2 in the bone marrow, and methylation based techniques to improve diagnostics in haematopathology.

Lars Nilsson is a Senior Consultant Hematologist (since 2005), Dept of Hematology, Oncology and Radiation Physics, Skåne University Hospital (SUS), Sweden. Medical training in Halmstad Hospital, Internal Medicine. MD, University of Lund, Sweden, 1987. Specialist in Internal Medicine 1991. Specialist in Hematology 1994. Member of the Nordic MDS Group and writing committee of the National Guidelines for Diagnosis and Treatment of MDS an the Nordic MPN Group.

Attilio Orazi M.D., FRCPath. (Engl.): MD from University of Milan, Italy. Trained in Anatomic Pathology, Hematopathology and Clinical Hematology first in the United Kingdom and later at the Istituto Nazionale Tumori of Milan, Italy. Board certified by the American Board of Pathology in Anatomic Pathology and Hematopathology. In addition, he is board certified in Clinical and Laboratory Hematology (Italy). He is a Fellow of the Royal College of Pathologists (England). Medical licensed in Texas, New York, Indiana. Overseas license of the GMC, London, UK and Italy. He lists 360 published contributions which include 290 peer-reviewed medical journal articles and 76 book contributions, including fourteen chapters/sections of the 2008 WHO Classification of Tumors of Hematopoietic and Lymphoid tissue and twenty of the 2016 update published in July 2017 by the IARC press. He served as a Senior Advisor for the 2016 update of the 4th edition of the WHO Classification of Tumors of the Hematopoietic and Lymphoid Tissues and as a CAC member for both 2008, 2016 and 2021 editions. Dr. Orazi has lectured extensively nationally (including at USCAP, ASH and ISLH) and internationally (25 countries). He is a member of several editorial boards. His research interests include diagnostic integration and prognostic assessment in bone marrow neoplasms with a focus on myeloid neoplasms, as well as diagnostic challenges in spleen pathology.

Anna Porwit is a Professor at the Department of Clinical Sciences, Division Oncology and Pathology, Lund University, Sweden, and Consultant in Hematopathology, Region Skåne. She received MD 1977 in Warsaw, Poland, Ph.D. (1988) at the Karolinska Institute, and pathology training at the Karolinska University Hospital, Stockholm, Sweden (completed 1993). 1998-2010 she was a Director of Hematopathology at the Department of Pathology, Karolinska University Hospital, combined with an appointment as Professor in Pathology at the Karolinska Institute since 2003. 2011-2015 she was a Professor in Pathology at the University of Toronto, ON, Canada, combined with an appointment as Consultant in Hematopathology at University Health Network and Medical Director of Flow Cytometry. She is a co-author of more than 200 original and review papers, some chapters in the “WHO Classification of Haematopoietic Malignancies” (both 2008 and 2016 editions), co-editor of the “Blood and Bone Marrow Pathology” book, published 2011 and co-editor of “Multiparameter Flow Cytometry in Diagnosis of Hematological Malignancies” book published 2018.

Dr. Quintanilla-Martinez is Professor of Pathology and Senior hematopathologist at the University hospital Tübingen´s Institute for Pathology since 2008. Dr. Quintanilla-Martinez received her MD from the National University of Mexico. She did her training in Internal Medicine and Pathology at the National Institute of Nutrition and Science in Mexico City. She completed her fellowships in hematopathology at University Hospital in Minneapolis, Minnesota, Sowthwestern Medical School and Harvard/Massachusetts General Hospital. She did her fellowship in molecular pathology at the National Cancer Institute, National Institutes of Health (NIH) in Bethesda. She has received several awards including the Rokitansky prize from the Austrian Society of Pathology, The Charlotte-Bühler stipendium in Austria, the Fogarty Award from the NIH and a Mantle cell lymphoma grant from the Lymphoma Research Foundation.

Richard Rosenquist Brandell holds a professorship in Clinical Genetics at the Dept of Molecular Medicine and Surgery, Karolinska Institutet, and works as a senior physician at Clinical Genetics, Karolinska University Hospital. He is also Director of Genomic Medicine Sweden, a national infrastructure for implementation of precision medicine. By employing a translational approach and utilizing cutting‐edge molecular tools, including next-generation sequencing technologies, Rosenquist Brandell has made outstanding contributions to our understanding of the mechanisms behind the development of chronic lymphocytic leukemia (CLL), the most common adult leukemia. His studies have identified novel prognostic and predictive markers, defined new clinically relevant CLL subgroups, as well as provided significantly improved risk stratification at the individual patient level. At Karolinska University Hospital, Rosenquist Brandell has been instrumental in setting up a specialized clinical laboratory for molecular diagnostics of hematological malignancies with all types of analysis spanning from chromosome analysis to next‐generation sequencing. He is actively leading several national and European networks aiming to harmonizing techniques for clinical diagnostics. Rosenquist Brandell is a member of the Nobel Assembly at Karolinska Institutet.

Dr. Sabattini is the Chief of the Haematopathology Unit at Bologna University Hospital. She has held a stable position as a pathologist and haematopathologist at Bologna University Hospital for 25 years and has been leading the Unit since 2015. Lymphomas and myeloproliferative disorders are the main areas of interest and research. She was a co-founder of the Italian Haematopathology Group of the Italian Society of Pathologic Anatomy and Cytology and have been an active member of the European Association for Haematopathology and European Bone Marrow Working group since 1990 for which she contributed in the organization of meetings and worshops. Dr. Sabattini has authored/ co-authored 227 peer-review papers.

Leonie Saft, MD, PhD, is a consultant hematopathologist at the Department of Clinical Pathology and Cancer Diagnostics, Karolinska University Laboratory (KUL), Solna, and affiliated to the Institute of Oncology & Pathology, Karolinska Institute (KI), in Stockholm. The Division of Hematopathology includes two subspeciality units, Morphology (cytomorphology and histology) and Flow cytometry, and covers the whole spectrum of diagnostic hematopathology. The flow cytometry laboratory is part of the Nordic FCM group and has close cooperation with NOPHO (Nordic Organization of Pediatric Hematology & Oncology). Dr Saft ’s clinical work and research at KUL focuses on bone marrow pathology and diagnostics and MRD follow-up of pediatric leukemias. Her past research has focused on myelodysplastic syndromes (MDS), and she received her Ph.D. from KI, Huddinge, on studies of TP53 mutations in MDS with deletion of 5q. She is member of the MDS diagnostic scientific committee, MDSDiagnosis.com, the Nordic MDS Group (NMDSG), and the European Leukemia Net Flow Working Group on MDS. Dr Saft received her medical training in Germany (Marburg and Frankfurt) and in the USA (UTMB, Galveston, Texas) with both German and American license (1996), and doctor medicine (1996) at the University of Frankfurt. She started her residency in Clinical Pathology at the Klinikum Darmstadt (1996-97), and University of Leipzig (1997-98). In 1998, she moved to Sweden and continued her residentship at the Akademiska University Hospital, Uppsala (1999-2001). Since 2001, she is employed at KUL in Stockholm.

Birgitta Sander received her MD from Karolinska Institutet and PhD in immunology from Stockholm University and Karolinska Institutet. She did a post-doc at DNAX Research Institute in Palo Alto, CA. Dr. Sander is since 2010 a professor in Pathology at Karolinska Institutet and a senior consultant at Department of Clinical Pathology and Cancer Diagnostics at Karolinska University Hospital and is subspecialized in haematopathology. Dr. Sander is a member and, since 2016, secretary-treasurer of the European Association of Haematopathology and a member of the European Bone Marrow Working Group. Her research group focusses studies of the molecular pathogenesis of mantle cell lymphoma, especially the role of SOX11 and cannabinoid receptors. She is also part of national and international research groups that study prognostic factors in follicular lymphoma and diffuse large B cell lymphoma, including the Lunenburg Lymphoma Biomarker Consortium. She has authored and co-authored >100 articles in the field. She is also a recognized as a painter with regular exhibitions at art galleries in Sweden.

Dr. Emina Emilia Torlakovic is a Clinical Professor of Pathology and Laboratory Medicine at the University of Saskatchewan in Canada, a Hematopathologist and Division Head of Hematopathology at Saskatchewan Health Authority. Dr. Torlakovic received her MD from the University of Zagreb Medical School, her PhD from the University in Oslo, and trained in Hematopathology at the University of Minnesota. She authored over 100 peer-reviewed papers and has written several book chapters and is the editor of the textbook Bone Marrow Immunohistochemistry, ASCP Press, 2009 and Associate Editor of AIMM. Dr. Torlakovic was a founding member of the NordiQC, co-founded Canadian Immunohistochemistry Quality Control (CIQC), and most recently founded and directs Canadian Biomarker Quality Assurance (CBQA) and CBQAReadout.ca, academic QA programs. Dr. Torlakovic is the Chair of the National Standards Committee for High Complexity Testing of the Canadian Association of Pathologists. She is the President of the International Society for Immunohistochemistry and Molecular Morphology (ISIMM) and a Board Member of the International Quality Network for Pathology (IQN Path). She was also a working panel member of the ASCO/CAP guidelines for ER/PGR testing in 2010 and 2020. Dr. Torlakovic has lectured nationally and internationally both in hematopathology and biomarker quality assurance.

Alexandar Tzankov is a surgical pathologist and Head of the Department of Histopathology and Autopsy at the Institute of Medical Genetics and Pathology of the University Hospital Basel. He is a member of numerous national and international scientific societies, such as the European Association for Haematopathology, the European Bone Marrow Working Group (of which he is also Chair Elect) and the International Council for Standardization in Haematology. He is associated editor of Pathobiology and editorial board member of Cancers (Basel), and an official expert in the field of pathology for the Swiss Accreditation Authority. His major interests and diagnostic expertise lie within haematopathology and mediastinal pathology. Alongside intensive tissue-based research activity on the interaction between SARS-CoV-2 and the human body in COVID-19 (http://unispital-basel.ch/rdp/Covid19-research) currently, his research group has for a long time been involved in translational investigations and precision medicine of lymphomas, particularly clonal relationships, molecular evolution of relapsing lymphomas and deciphering the genetic landscape of marginal zone lymphomas (http://unispital-basel.ch/rdp/hematolymphoid-tumors). He has authored or co-authored >400 papers (orcid.org/0000-0002-1100-3819). He has a passion for downhill and cross-country skiing, hiking and mountain-biking.

A.A. van de Loosdrecht passed Medical School (cum laude) in 1989 at the VU University Medical Center in Amsterdam (VUmc), The Netherlands. After a 4th years scientific laboratory training in cell biology, immunology and hematology he received his PhD graduation (cum laude) in 1993 at the department of Hematology (VUmc) on the thesis; ‘Monocyte mediated cytotoxicity in acute myeloid leukemia; Mechanisms and clinical implications’. In 1995 he graduated in Immunology. From 1993-1998 he followed clinical training in Internal Medicine followed by a fellowship in hematology (Department of Internal Medicine and Hematology at the Groningen University Medical Center, Groningen, Netherlands). From 2000, he is a staff member, since 2009 an associate professor and since 2012 a full professor of hematology at the department of Hematology, Amsterdam UMC, location VUmc, Amsterdam. His particular scientific experiences and interests are on translational hematology. He is projectleader/principal investigator of the preclinical and translational immunotherapy programs in myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The major research lines focus on the immunopathogenesis of MDS/AML and on the development of leukemic dendritic cell vaccines for active specific immunization in patients with minimal residual disease (MRD) in AML and MDS. Since 2016 he is coordinator of HORIZON2020, AML-VACCiN program dealing with Dendritic Cell vaccination in AML and PI of the clinical program. He is project leader/principle investigator of clinical (translational) programs dealing with the treatment of low and high risk MDS. Regarding MDS, research focuses on the implementation of flow cytometry in the diagnosis, prognostication and monitoring of MDS. As such he is participant of the HORIZON2020 MDS-Right program. He is chair of the working group MDS of the Dutch Society of Cytometry on the implementation of flowcytometry in MDS and initiated a platform within the ELN on the implementation of flowcytometry in MDS in Europe.

Dr. Sa Wang is a professor of pathology and the section chief of the flow cytometry in the Department of Hematopathology, The University of Texas MD Anderson Cancer Center. Dr. Wang’s clinical expertise and research interest are in hematolymphoid neoplasms including the use of histopathology, flow cytometry and molecular genetics for disease diagnosis, classification and risk stratification. Dr. Wang has published over 260 original studies, 31 invited review articles and 25 book chapters for 7 reference books, an editor and author for “Diagnosis of Blood and Bone Marrow Disorders”. Dr. Wang is an associate editor for Cytometry B Clinical Cytometry, and a two term council member for the International Clinical Cytometry Society. Dr. Wang has taught or directed many CME courses and served as organizer, moderator, panelist, or session chair at various meetings and workshops sponsored by USCAP, CAP, ASCP, ICCS, IAP, AMLI, SH-EAH, and EH etc, and an invited speaker at many institutions. Dr. Wang has participated in the writing practice guidelines for acute leukemia diagnosis as a joined effort by the CAP and ASH. Dr. Wang has obtained multiple industrial funds to study tumor biomarkers.

Professor Bogna Ziarkiewicz-Wróblewska graduated from the Faculty of Medicine of the Medical University of Warsaw in 1983. 1987, working at the Department of Cardiology, she gained a specialization in internal medicine. After internship under the supervision of Professor George Delsol in the Department of Pathology in Toulouse, she decided to become a hematopathologist which is her main field of interest. In 1998, she obtained a specialization in surgical pathology. Since 1990 she has worked at the Department of Pathology, Medical University of Warsaw with hematopathology and liver pathology. 1993, she defended her PhD and 2008 she obtained her docent degree based on the thesis: “Prognostic factors of HCV recurrence after OLT in adults”. She is professor in pathology since 2016. She is active in the student teaching at WUM and in postgraduate teaching. She is an author of 184 publications, and actively participates in EAHP/EBMWG congresses. Prof. B. Ziarkiewicz-Wróblewska is a member of the Polish Society of Pathology, the European Association for Haematopathology, the Polish Transplantation Society, the Polish Society for the Study of the Liver, the Polish Society of Medical Biology. Between 2016 and 2021 she has served as a Board Secretary of the European Bone Marrow Working Group.